Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

11 of 40

Bahija Jallal, Executive Vice President for R&D at MedImmune

Bahija Jallal figures China will soon be the world's largest market for pharmaceuticals, but navigating the country's fractured regional markets, byzantine regulatory processes and logistical roadblocks are a tall order for any multinational drugmaker. That's why her company, MedImmune, chose to partner with WuXi PharmaTech to develop biologics for the Chinese market, she said, leveraging parent company AstraZeneca's ($AZN) presence in the country to fast-track new therapies. In China, local expertise is priceless, Jallal said, and if the WuXi joint venture is a success, MedImmune will expand its efforts and market China-developed treatments across Asia.